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The main function of the skin is to protect the body
from infection, dehydration, and other environmental
insults by creating an impermeable barrier of corni¢ed
cell layers, the stratum corneum. In contrast to cells in
culture, tissue-engineered skin equivalents contain well-
developed basal, spinous, granular, and corni¢ed cell
layers providing an excellent model to study the tissue
response to barrier disruption. After 7 d of culture at
the air^liquid interface the barrier of the tissues was dis-
rupted by short exposure to acetone and the global gene
expression pro¢le of the tissues was evaluated using
DNA microarrays.We found that tissue-engineered skin
responds to barrier disruption by a two-wave dynamic
response. Early on, the cells upregulate signal transdu-
cing, stress, proliferation, and in£ammation genes to
protect the tissue and possibly to communicate the da-
mage to the immune system and neighboring tissues.
At later times, pro-in£ammatory cytokines and some
growth-related genes are signi¢cantly reduced but en-
zymes that participate in lipid synthesis increase, sug-
gesting that the epidermal cells attempt to restore the
lost barrier. Quantitative immunostaining for the pro-
liferation antigen Ki67 revealed that barrier disruption
by acetone increased proliferation by 4-fold in agree-
ment with the microarray data and previous in vivo stu-
dies. Our work suggests that functional genomics may
be used in tissue engineering to understand tissue devel-
opment, wound regeneration, and response to environ-
mental stimuli. A better understanding of engineered
tissues at the molecular level may facilitate their appli-
cation in the clinic and as biosensors for toxicologic
testing. Key words: tissue engineering/genomic skin/DNA
microarrays/wound healing. J Invest Dermatol 121:368 ^382,
2003
T
issue engineering seeks to create three-dimensional
tissue substitutes that may be used to restore tissue
function and as biologic models for studying tissue
development and disease pathogenesis (Langer and
Vacanti, 1993; Berthiaume andYarmush, 1995; Gri⁄th
and Naughton, 2002). Engineered tissues can also be used as rea-
listic biologic models to obtain fundamental understanding of
the structurefunction relationships under normal and disease
conditions and as toxicologic models to facilitate drug develop-
ment and testing (Garlick and Taichman, 1994; Andreadis et al,
2001; Geer et al, 2002; el-Ghalbzouri et al, 2002).
The outer layer of the skin, the epidermis, establishes a barrier
that protects the body from infection and water loss. The epider-
mal barrier function is maintained by a continuous intercellular
lipid phase of ceramides and other sphingolipids (Nishijima et al,
1997).When this barrier function is perturbed by application of
mechanical forces (tape stripping), chemical solvents (e.g., acet-
one) or detergents (e.g., sodium dodecyl sulfate) the epidermis
responds in multiple ways to restore the barrier function. The
epidermal response includes an immediate secretion of lamellar
bodies (Man et al, 1993) and an increase in the synthesis of sterols
(Feingold et al, 1990), fatty acids (Grubauer et al, 1987), sphingoli-
pids (Holleran et al, 1991a; 1991b), and cytokines (Wood et al,
1992). In addition, barrier perturbation accelerates DNA synthesis
and induces a hyperproliferative response known as epidermal
hyperplasia (Proksch et al, 1991; 1993; Ashida et al, 2001).
In contrast to cells in culture, engineered skin equivalents mi-
mic human epidermis in terms of tissue architecture and exhibit
signi¢cant barrier function (Nolte et al, 1993; Andreadis et al,
2001). After a week of culture at the air^liquid interface they form
a well-strati¢ed epidermis with basal, spinous, granular, and cor-
ni¢ed layers. Biochemical and ultrastructural studies have shown
that these epidermal cultures exhibit metabolic and di¡erentia-
tion programs similar to human skin (Asbill et al, 2000; Ponec
et al, 2000; Robinson et al, 2000;Wagner et al, 2001; Hayden et al,
2003). Therefore, three-dimensional engineered tissues may pro-
vide a controlled yet realistic model to study the molecular me-
chanisms of barrier disruption and identify the genes that
participate in this process.
The advances in tissue engineering are accompanied by the de-
velopment of powerful new genetic technologies, which permit
the simultaneous quantitation of large numbers of genes by hy-
bridization on a solid surface (Brown and Botstein, 1999; Graves,
1999). DNA microarrays have been used to address a variety of
biologic problems including cell cycle and metabolism of
yeast cells (Shalon et al, 1996; DeRisi et al, 1997; Lashkari et al,
1997; Spellman et al, 1998; Toronen et al, 1999), response of human
Reprint requests to: Stelios T. Andreadis, Bioengineering Laboratory,
908 Furnas Hall, Department of Chemical Engineering, University at Buf-
falo, The State University of New York, Amherst, NY 14260; Email:
sandread@eng.bu¡alo.edu
Abbreviations: ACBP, acyl-coA-binding protein; EGR-1, early growth
response protein; FRA-1, Fos-related antigen; HSP, heat shock protein 1;
IGFBP1, insulin-like growth factor binding protein 1; IL2-Ra, interleu-
kin-2 receptor a subunit; PLA2, phospholipase A2.
Manuscript received February 4, 2003; revised March 10, 2003; accepted
for publication March 12, 2003
0022-202X/03/$15.00 . Copyrightr 2003 by The Society for Investigative Dermatology, Inc.
368
¢broblasts to serum (Iyer et al, 1999), development of the central
nervous system (Wen et al, 1998), di¡erentiation of hematopoietic
cells (Tamayo et al, 1999), branching morphogenesis of the collect-
ing system of the kidney (Pavlova et al, 1999), and progression and
classi¢cation of human cancers (DeRisi et al, 1996; Golub et al,
1999; Perou et al, 1999). More recently, DNA arrays were em-
ployed to obtain global gene expression pro¢les of human hyper-
trophic scars (Tsou et al, 2000) and human skin following surgery
(Cole et al, 2001a; 2001b), ultraviolet (UV) radiation (Li et al, 2001;
Sesto et al, 2002), photodamage (Urschitz et al, 2002), or burn
(Spies et al, 2002). These studies provided a global view of gene
expression and identi¢ed previously unsuspected genes that may
be important in skin physiology and wound healing.
In this study, we used cDNA microarray technology to identi-
fy genes that are expressed when engineered skin equivalents are
subjected to barrier disruption using acetone. Treatment with
acetone resulted in expression of several genes involved in
growth, signaling, transcription, cytoskeletal organization, apop-
tosis, and in£ammation. Initially the tissues responded by upre-
gulating genes related to signal transduction, in£ammation, and
protection from apoptosis. At later times expression of in£amma-
tion-speci¢c genes decreased whereas expression of genes related
to di¡erentiation and lipid synthesis increased, indicating the in-
itiation of barrier recovery. Indeed, 24 h after treatment immuno-
histochemistry showed a signi¢cant increase in basal cell
proliferation in agreement with the increased expression of
growth-related genes. In addition, we identi¢ed novel genes that
were expressed in response to acetone treatment and were not
previously known to be expressed by keratinocytes. Our data
suggest that functional genomics can be used in tissue engineer-
ing to study tissue development, response to environmental sti-
muli, and wound regeneration.
MATERIALS AND METHODS
Culture of skin equivalents and barrier disruption Skin equivalents
(Epiderm) were provided by MatTek (Ashland, MA). The tissues were
cultured at the air^liquid interface in tissue culture inserts placed in six-
well plates containing 1 ml of culture medium. Upon receipt the tissues
were placed in culture for 1 h and wounded by application of absolute
acetone atop the tissue for the indicated times. At the end of the exposure
period, the acetone was drained out and the inserts were placed in six-well
plates containing fresh medium.
Tissue viability The viability of the tissues was assessed with the MTT
assay kit (MatTek) as per the manufacturer’s protocol. Brie£y the tissues
were incubated in MTT for 3 h followed by overnight incubation in lysis
bu¡er (MatTek). The optical density at 570 nm was measured with an
absorbance microplate reader (SpectraMax 340, Molecular Devices, Menlo
Park, CA). The values were corrected for nonspeci¢c background by
subtracting the optical density at 650 nm. The absorbance of wells
containing lysis bu¡er was subtracted as background.
Transepidermal electrical resistance Barrier disruption studies were
done by measuring the transepidermal electrical resistance with an
EVOM Epithelial Voltohmmeter equipped with an Endohm Tissue
Resistance Measurement Chamber (World Precision Instruments,
Sarasota, FL). Brie£y, the Epiderm insert was placed into an Endohm
chamber containing a small volume of phosphate-bu¡ered saline (PBS).
An additional 300 ml of PBS was applied to the top surface of the
Epiderm tissue. The chamber lid containing the top electrode was then
inserted and the resistance was measured. The resistance of a blank insert
without an Epiderm tissue was subtracted from all experimental
measurements.
Histology and immunohistochemistry The morphology of the
tissues was assessed by a standard hematoxylin and eosin stain of para⁄n-
embedded samples. For immunohistochemistry para⁄n-embedded tissues
were prepared by ¢xation in 10% phosphate-bu¡ered formalin (Fisher
Scienti¢c, Pittsburgh, PA) for 2 h at room temperature. The tissues were
then dehydrated by ethanol/xylene washes and embedded in para⁄n after
overnight in¢ltration at 601C. Para⁄n sections (5 mm thick) were
depara⁄nized by reverse ethanol/xylene washes. For detection of Ki67 the
tissue sections were boiled in citrate bu¡er (0.01 M, pH¼ 6.0) for 8 min.
The sections were then blocked for 1 h (blocking solution 10% horse
serum in PBS) and incubated with 100 ml of mouse antihuman Ki67 (1:100
dilution in blocking solution; 30 min at 251C; Zymed Laboratories, San
Francisco, CA). The tissue sections were washed ¢ve times in PBS and
then incubated with biotinylated horse antimouse antibody (1:200
dilution in blocking solution; 30 min at room temperature). The slides
were then incubated with avidinhorseradish peroxidase for 30 min and
developed with a substrate kit (Vector Laboratories, Burlingame, CA).
Slides were washed ¢ve times with PBS, followed by a 5 min wash with
tap water, and counterstained with hematoxylin for 55 s (Harris
hematoxylin). The slides were washed with tap water for 10 min and
mounted with an aqueous mounting medium (Crystal/Mount, Biomeda,
Foster City, CA).
RNA isolation At the indicated times postwounding, wounded and
unwounded tissues were lyzed in lysis bu¡er using a pellet pestle mixer
(Kontes, Vineland, NJ) and total RNA was isolated using the SV RNA
isolation kit (Promega, Madison,WI), as per the manufacturer’s protocol.
The puri¢ed RNAwas incubated in 2.5 vol of sodium acetate and 0.1 vol
of 80% ethanol (overnight at ^201C) and pelleted by centrifugation
(16,000g at 41C). After two washes with 80% ethanol, the RNA pellet
was resuspended in nuclease-free water. The amount of RNA was
quanti¢ed using a spectrophotometer (Bio-Rad Laboratories, Hercules,
CA) and the quality was veri¢ed by electrophoresis on a 1% agarose
denaturing gel.
cDNA arrays We used Atlas Human 1.2 microarrays (Clontech
Laboratories, Palo Alto, CA) that contain 1176 human cDNAs, nine
housekeeping genes, and three negative controls. Each experiment
contained triplicate samples (i.e., three skin equivalents) for each
condition (wounded, unwounded) and each time point. RNA from one
sample was used for cDNA array hybridizations except for RNA from
wounded tissues 8 h post-treatment that was a mixture of RNA from
two identically treated tissues.
Generation of the cDNA probe and hybridization with the arrays were
performed using the Atlas membrane hybridization kit (Clontech
Laboratories) as per the manufacturer’s protocol. Brie£y 33P-labeled
cDNA was prepared by reverse transcription using 200 units of
Superscript II (Invitrogen, Carlsbad, CA), 0.5 mM each of dATP, dGTP,
dTTP (Promega, Madison, WI), and 35 mCi of 33P-labeled dCTP
(Amersham Pharmacia, Piscataway, NJ). The labeled probe was hybridized
overnight to cDNA arrays in ExpressHyb (Clontech) at 681C with
continuous agitation. After extensive washing, the membranes were
wrapped into Saran wrap and exposed to phosphorimaging screens
(Packard Instruments, Meridien, CT) for 5 d at room temperature. Images
were acquired in a cyclone phosphorimager (Packard Instruments) and the
intensities of each spot were quanti¢ed using the AtlasImage software
(Clontech).
Microarray analysis The background intensity of each array was set as
the median intensity of the ‘‘blank space’’ between the spots. The adjusted
intensity was then calculated by subtracting the background intensity from
the raw intensity value. A signal was considered genuine if the adjusted
intensity was twice the background intensity. A total of 154 genes were
selected to have genuine signal and hence for further analysis.
The e¡ects of acetone treatment were measured by comparing the
expression level of each gene in the control versus wounded tissues at the
same time point. For comparison between two membranes, we used
global normalization to account for systemic variation arising from
di¡erent RNA preparations and hybridization e⁄ciencies to di¡erent
membranes.We de¢ned a normalization coe⁄cient to be the ratio of the
sum of the adjusted intensities in the two arrays to be compared. The
relative expression of each gene was calculated as the ratio of its intensity
in the acetone-treated tissue over the intensity in the control tissue
multiplied by the normalization coe⁄cient. A gene was considered
upregulated (downregulated) if its relative expression was equal to or
greater (smaller) than 2.0 (0.5) and if the di¡erence between the two
intensities was greater than the di¡erence threshold. The di¡erence
threshold was de¢ned as the sum of the backgrounds of the two arrays
under comparison.
The genes were grouped into clusters using self-organizing maps (SOM)
using the Genecluster 1.0 software (Tamayo et al, 1999), which is available at
http://www-genome.wi.mit.edu/cancer/software/software.htm.
Quantitative RT-PCR For reverse transcription 2 mg of RNA was
mixed with 1 ml each of oligo-dT (Invitrogen) and dNTP mix (10 mM,
Fisher Scienti¢c, Suwanee, GA). The volume was brought to 13 ml by
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DEPC water and the mixture was heated at 651C for 5 min followed by
addition of 4 ml of 5 reaction bu¡er (Invitrogen) and 2 ml dithiothreitol
(Invitrogen). After 2 min incubation at 421C, 1 ml of reverse transcriptase
(200 U per ml, Super Script II; Invitrogen) was added and the mixture was
further incubated at 421C for 50 min. At the end of the incubation period
reverse transcriptase was inactivated by heating at 701C for 15 min.
Quantitative PCR was performed using the iCycler (Bio-Rad
Laboratories). SYBR Green I (Molecular Probes, Eugene, OR) was used
to detect double stranded DNA after each ampli¢cation cycle. The
reaction was carried out in a volume of 50 ml containing 2 ml of cDNA,
200 mM of each dNTP, 0.2 mM of each primer (Sigma Genosys,
Woodlands, TX), 1.25 units of Taq Polymerase (HotMaster, Eppendorf,
Westbury, NY), and PCR bu¡er (Eppendorf). The primers were designed
using the Clone Manager software (Educational Software, Durham, NC)
and the reaction conditions (concentration of MgCl2 and annealing
temperature) were optimized for each transcript to minimize
primerdimer formation (Table I). Each reaction comprised 40 cycles
each with melting at 941C for 20 s, annealing at the indicated temperature
(Table I) for 20 s, and extension at 721C for 25 s.The £uorescence intensity
was recorded at the indicated temperature (Table I) after the extension step
of each cycle. The speci¢city of the PCR products was veri¢ed using the
melt curve generated by the iCycler and by electrophoresis on 2% agarose
gels.
Quantitative real-time PCR data analysis The threshold cycle (Ct) of
each reaction was de¢ned as the cycle at which the £uorescence was 10
times the mean of the standard deviations of the previous 10 cycles
excluding the ¢rst one (iCycler software, version 3.0; Bio-Rad
Laboratories). For each primer pair, the value of Ct was measured at four
serial 10-fold dilutions (D) of the cDNA template. Each reaction was
performed in triplicate. The e⁄ciency of the PCR (Z) for each gene was
calculated from the slope of the standard curve that was generated by
plotting the logarithm of the fold-dilution (log D) versus the threshold
cycle (Ct). Using the e⁄ciency of the reaction for each primer pair and
the average Ct values of the undiluted cDNA templates, we calculated the
ratio R of the amount of each gene in the wounded (Ct
w) over unwounded
tissues by the following equation:
R ¼ ð1þ ZÞCUnwoundedt  C
Wounded
t
Each experiment was conducted twice with RNA from two independent
tissues.
RESULTS
Acetone treatment decreases the viability of engineered skin
equivalents To disrupt the barrier of tissue-engineered skin
equivalents we treated the tissues by application of acetone (350
ml per well) for various times ranging from 5 to 45 min. At
di¡erent times postwounding the metabolic activity of the
tissues was evaluated using the MTT assay (Fig 1). For short
acetone treatment (5 min), the metabolic activity decreased
linearly with time, reaching 67% of the initial activity by 24 h
postwounding. For the 10 min treatment the activity dropped to
63% of the initial value by 4 h and increased to 69% at 24 h
postwounding (the increase from 63% to 69% was not
statistically signi¢cant, p¼ 0.3). Acetone treatment for 15 and 30
min led to 86% and 88% loss of metabolic activity, respectively,
by 4 h postwounding, indicating signi¢cant loss of tissue
viability. Longer exposures (45 min) led to death of the tissues,
as suggested by very low values of metabolic activity
immediately after exposure to acetone. Aiming for a level of
acute barrier disruption that had a signi¢cant e¡ect on
engineered tissues without killing them we chose the 10 min
acetone treatment for the rest of our experiments.
Acetone-induced acute barrier disruption To evaluate the
loss of barrier of engineered tissues we measured the
transepidermal electrical resistance of tissues at 4, 8, and 24 h
after 10 min acetone treatment. The results are summarized in
Fig 2. Surprisingly the barrier of untreated tissues increased by
50% after 4 h (p¼ 0.025) and remained at elevated levels
thereafter. In contrast, the barrier of acetone-treated skin
equivalents decreased by 60% (p¼ 0.029) immediately after
wounding (at time t¼ 0). Although there was a 40% recovery 8
h later (p¼ 0.064), the barrier remained signi¢cantly lower even
24 h after treatment.
Acetone a¡ects tissue morphology in a time- and position-
dependent fashion Next we used histology to further assess
the e¡ects of 10 min acetone treatment on engineered tissues.
Figure 3 shows that acetone a¡ected the tissues in a spatially
and temporally dependent manner. At early times (4 h) there
was no signi¢cant histologic di¡erence between wounded and
unwounded tissues. By 8 h post-treatment the stratum corneum
started to lose its structural integrity and a few suprabasal and
granular cells showed loss of cytoplasmic content. These e¡ects
became more pronounced at 24 h. The e¡ects of acetone were
not detrimental, however, as the wounded tissues were
metabolically active (Fig 1) and they responded to barrier
disruption by signi¢cantly increasing the proliferation of basal
cells compared to unwounded tissues (Fig 6).
Changes in gene expression by acetone treatment using
cDNA arrays To evaluate the response of engineered skin
equivalents to acute barrier disruption, we measured global gene
expression pro¢les using cDNA microarrays. The tissues were
treated with acetone for 10 min and at 4, 8, and 24 h
postwounding RNA was isolated from the tissues and reverse
transcribed to generate 33P-labeled cDNA. Radiolabeled cDNA
was then hybridized to Atlas membranes, which contain 1176
genes. The Atlas software (Clontech) was used to quantify the
intensity of each spot on the nylon arrays.
For comparison between the treated and control samples, the
intensity of each gene was normalized to the average intensity of
the array and genes were considered ‘‘on’’ when the signal
Table I. Primer sequences and PCR conditions
Gene Primer sequences temperature (1C) Annealing temperature (1C) Reading (1C) Mg2þ (mM) Product size
Egr-1 Forward 50 -GATCCACTTGCGGCAGAAGG-30 55 87 3 324
Reverse 50 -GCGCTGAAGGAGTTGGTGAC-30
FRA-1 Forward 50 -AGCCCAGCAGAAGTTCCACC-30 65 87 3 332
Reverse 50 -CCAGTTTGTCAGTCTCCGCCTG-30
PLA2 Forward 50 -GCCTGCATGAAGTCTGTAAC-30 55 70 3 324
Reverse 50 -CTCAGCCAAGTAACGGTAGT-30
ACBP Forward 50 -AGAGGAGGTTAGGCACCTTA-30 60 70 2.5 380
Reverse 50 -CTGTTAGAGCCGTATGGTGA-30
Thymosin b10 Forward 50 -GGAGACGCAGGAGAAGAACA-30 60 70 2.5 139
Reverse 50 -TGGCTCTTCCTCCACATCAC-30
GAPDH Forward 50 -CCTGCACCACCAACTGCTTA-30 60 70 2.5 343
Reverse 30 -GCCTGCTTCACCACCTTCTT-30
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intensity was twice the background. At each time point gene
expression was evaluated in cognate controls to account for any
changes of untreated samples with time. A gene was considered
upregulated or downregulated if the ratio of normalized gene
intensity of the acetone-treated versus control tissues was higher
than 2 or lower than 0.5, respectively. Using these two ¢lters, we
identi¢ed 154 genes that were upregulated or downregulated at
one or more times after treatment (Table II).
Cluster analysis We used SOM to group genes with the same
dynamic behavior into one cluster. In SOM each node represents
a cluster of genes with similar kinetic pro¢les.With only a few
nodes, there are no distinct patterns and there is large within-
cluster scattering. As the number of nodes increases, distinctive
and tight clusters emerge.
We settled for a 33 SOM because it represents all dynamics
of gene expression. In Fig 4, cluster 0 represents genes that do not
change with time. Clusters 1 and 2 include genes that are induced
early and then come back to the normal level or decrease after 24
h. Genes that are induced 8 h postwounding and then come back
to the normal level or decrease are represented by clusters 3, 5,
and 8. Finally, clusters 4, 6, and 7 contain genes that are induced
late at 24 h postwounding. The numerical values of the ratios of
each gene at 4, 8, and 24 h postwounding are listed inTable II.
Dynamics of gene expression
Early genes The genes that are upregulated at 4 h after acetone
treatment are involved in ¢ve major functions: signaling, tran-
scription, cytoskeletal organization, apoptosis, and in£ammation.
Signaling genes include mitogen-activated protein kinase acti-
vated kinase 2, PTPCAAX1 nuclear tyrosine phosphatase,
growth-factor-receptor-bound protein 2, Ras-related protein,
and p21/K-ras 2B. Several transcription factors are upregulated,
such as early growth response protein (EGR-1), which activates
genes required for mitogenesis, and c-myc, which induces hyper-
proliferation, reduces di¡erentiation, and increases resistance of
keratinocytes to UV-induced apoptosis (Waikel et al, 1999). In ad-
dition, acetone signi¢cantly upregulates GATA2 (6-fold), a gene
that is expressed in endothelial cells (Dorfman et al, 1992) but as
yet unknown to be expressed in keratinocytes. Genes that are in-
volved in cytoskeletal organization (ezrin, cortactin, thymosin
b10, a1-catenin) and protection against apoptosis (adenosine A1
receptor, Fos-related antigen (FRA-1), and heat shock protein 1
(HSP70)) are also upregulated. Finally, at this early stage after
barrier disruption keratinocytes increase expression of in£amma-
tory genes such interleukin-2 receptor a subunit (IL2-Ra)
and RANTES, a pro-in£ammatory cytokine, possibly to alert
the immune system and surrounding tissues about the loss of
barrier.
Several genes are downregulated at 4 h postwounding. These
include certain transcription factors such as ROR-a1 (Chauvet
et al, 2002; Jarvis et al, 2002); GATA3, which regulates the expres-
sion of the T cell receptor a gene (Ho et al, 1991) and is downre-
gulated during hair cell di¡erentiation in the mouse cochlea
(Rivolta and Holley, 1998); and HIF-1a, which is expressed by
basal keratinocytes next to the wound edge and is markedly in-
creased in epidermal dysplasia and squamous carcinomas (Elson
et al, 2000). In addition, acetone decreases expression of the corni-
¢ed envelope genes including strati¢n (Dellambra et al, 1995), cor-
neodesmosin (Allen et al, 2001), calgranulin A, and calgranulin B
(Katz and Taichman, 1999). Surprisingly, genes involved in
metabolism and oxidative stress such as glucose transporter and
glutaredoxin are also downregulated.
Intermediate genes By 8 h postwounding the tissues shows ele-
vated levels of antiapoptotic genes including HSP90A, methio-
nine aminopeptidase 2, CAP2, BAG-1, adenosine A1 receptor
(43-fold), and FRA-1 (40-fold). Some of the genes related to
cell signaling (mitogen-activated protein kinase activated kinase
2 and Ras-related protein) and cytoskeletal organization (ezrin,
thymosin b10) continue to be elevated. In addition, growth-pro-
moting genes are upregulated including CDC-like kinase 1, insu-
lin-like growth factor binding protein 1 (IGFBP1), fte-1, EGR-1,
cyclin K (43-fold), and amphiregulin (43-fold).
Notably, FRA-1, a transcription factor that activates the pro-
moter of keratin-6 (Ma et al, 1997), is exceedingly upregulated
by approximately 40-fold. Keratin-6 is a marker of epidermal hy-
perproliferation in wound healing, dermal disorders (Han et al,
2001), and in£ammatory diseases such as psoriasis (Mommers
et al, 2000). Accordingly, keratin-6 is induced by tumor necrosis
factor a (Komine et al, 2000) and interleukin-1, a proin£amma-
tory cytokine that is released by keratinocytes in response to in-
jury (Komine et al, 2001). These data suggest that 8 h after
Figure1. Acetone treatment decreased the metabolic activity of tis-
sue-engineered skin. Skin equivalents were wounded by application of
acetone in the tissue culture inserts for the indicated times. The acetone
was removed, fresh medium was added in the lower compartment, and
the tissues were returned to culture at the air^liquid interface. At the indi-
cated time after wounding, the tissues were incubated with MTT for 3 h
and then lyzed in extractant solution overnight. The next day the optical
density values were measured at 570 nm and corrected for nonspeci¢c
background by subtracting the optical density at 650 nm. The absorbance
of wells containing lysis bu¡er was subtracted as background. Each point
shows the mean and standard deviation of duplicate samples in a represen-
tative experiment (n¼ 2).
Figure 2. Acetone treatment disrupted the epidermal barrier. The
tissues were wounded by application of absolute acetone to the apical sur-
face for 10 min. At the end of the exposure time, the remaining acetone
was removed and the tissues were placed in fresh culture medium. At the
indicated time points, transepidermal electrical resistance was measured
with an EVOM Epithelial Voltohmmeter equipped with an Endohm
Tissue Resistance Measurement Chamber as described in Materials and
Methods.
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Figure 3. Acetone a¡ected skin equivalents in a time- and position-dependent fashion. Skin equivalents were wounded by application of acetone
in the tissue culture inserts for 10 min. The acetone was removed, fresh medium was added in the lower compartment, and the tissues were returned to
culture at the air^liquid interface. Hematoxylin and eosin staining of para⁄n-embedded wounded and unwounded tissue sections at 4 h (A), 8 h (B), and 24
h (C) postwounding (magni¢cation 40 ).
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exposure to acetone cells continue with the genetic program that
protects them against apoptosis and promotes growth to replace
the lost tissue and eventually restore the barrier.
Interestingly, genes related to in£ammation such IL2-Ra and
RANTES are also highly upregulated at this time, with levels
increased by 45- and 12-fold, respectively. This ¢nding suggests
that the epidermis allocates a lot of resources to communicate
the insult to the immune cells (RANTES is a chemoattractant
for blood monocytes, memory T helper cells, and eosinophils),
possibly to protect the body against invaders (e.g., viruses, bacter-
ia) that may take advantage of the reduced barrier. The epidermis
also communicates with endothelial cells by upregulation of vas-
cular endothelial growth factor (2-fold), possibly to increase vas-
cularization and support the increase in proliferation.
Interestingly, genes that are involved in the formation of the cor-
ni¢ed envelope (calgranulin A and B) and metabolism (glucose
transporter and glutaredoxin) continue to be reduced in acet-
one-treated tissues.
In summary, 4 and 8 h after acetone treatment engineered skin
equivalents upregulate factors that seem to have protective e¡ects
against injury, other components that contribute to reorganiza-
tion of the cytoskeleton, and pro-in£ammatory cytokines that
signal to neighboring tissues. In addition, the tissues increase ex-
pression of growth-promoting transcription factors and decrease
expression of di¡erentiation-related transcription factors and
components of the corni¢ed envelope. Collectively, these data
may suggest that the epidermis responds to acetone treatment by
protecting cells from death and signaling to neighboring tissues.
At this time, the tissue downregulates pathways related to di¡er-
entiation and instead prepares for increased proliferation to re-
place the number of injured cells.
Late genes The most highly upregulated genes are ADORA1
(22-fold), which confers protection against cell death, thymosin
b10 (14-fold) and vascular endothelial growth factor (9-fold).
Other highly upregulated genes that confer protection against
apoptosis include heat shock proteins (HSP90, HSP70, heat shock
cognate 71), protease inhibitor 8, BAG-1, and thioredoxin-depen-
dent peroxide reductase, which participates in processes of cell re-
pair from oxidative damage. Growth-promoting genes include
CDC-like kinase 1, NDKA, and highly upregulated fte-1 (46-
fold), which accumulates in cells undergoing DNA synthesis
(Kho et al, 1996). Interestingly, genes that inhibit growth of
epithelial cells (CRAF1; growth arrest and DNA-damage-induci-
ble protein, GADD45) are also upregulated (48-fold and 43-
fold, respectively), whereas pro-in£ammatory genes such as IL2-
Ra and RANTES are signi¢cantly reduced, suggesting that the
epidermis may be departing from an in£ammatory and hyper-
proliferative state to start a di¡erentiation program.
Indeed, genes implicated in lipid metabolism are either upre-
gulated (acyl-coA-binding protein (ACBP), IGFBP1) or return to
normal levels (phospholipase A2 (PLA2)). ACBP is involved in
regulation of lipid and cholesterol synthesis of epidermal kerati-
nocytes (Alho et al, 1993) and IGFBP1 increases the mitogenic ef-
fects of IGF-1 on keratinocytes (Kratz et al, 1992); and may also be
involved in lipid metabolism (Ukkola et al, 2001). PLA2 is in-
volved in pro-in£ammatory processes in several tissues (Schadow
et al, 2001) enhancing the release of arachidonic acid and forma-
tion of prostaglandin (Han et al, 1999; Murakami et al, 1999). In
skin, however, PLA2 is also involved in maintaining epidermal
homeostasis and barrier function by participating in the forma-
tion of nonpolar lipids that are needed in the stratum corneum
(Mao-Qiang et al, 1996). Therefore, restoration of the mRNA le-
vels at 24 h after acetone treatment may suggest that the epider-
mis is trying to restore the lost barrier.
Quantitative RT-PCR We performed quantitative RT-PCR to
quantify the levels of a select group of genes and verify the
cDNA microarray data. We have chosen two growth-related
genes (EGR-1, FRA-1), a gene involved in cytoskeletal14
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organization (thymosin b10), and a gene involved in lipid
metabolism (PLA2). The ratio of expression of each gene in the
wounded tissue over the expression in the control at the same
time point was plotted as a function of time. The ratios of the
same genes measured by cDNA microarrays were also plotted
for comparison (Fig 5).
In general, there is qualitative agreement between microarrays
and real-time PCR. Both techniques show that FRA-1 is
signi¢cantly elevated at 4 and 8 h but decreases at 24 h, although
the ratio measured by real-time RT-PCR is signi¢cantly lower
than the ratio measured by microarrays (Fig 5A). Similarly, both
methods showed that EGR-1 was highly upregulated at 4 h but
decreased at 8 and 24 h (Fig 5B). Thymosin b10 showed an
increase at 4 h followed by a small decrease at 8 h (primarily in
real-time PCR) and a signi¢cant elevation at 24 h (especially in
microarrays) (Fig 5C). Finally, the two methods show a decrease
in the levels of PLA2 with acetone treatment (although at
di¡erent times, i.e., at 4 h in microarrays and at 8 h in real-time
PCR), followed by a return to normal levels (ratio close to 1.0) at
24 h postwounding (Fig 5D).
Acetone increases basal cell proliferation The gene
expression data showed that the mRNAs of several growth-
related genes were upregulated at 4 and 8 h after acetone
treatment. To examine if the molecular results translated into an
increase in cell proliferation, we stained sections of para⁄n-
embedded skin equivalents for the nuclear proliferation antigen
Ki67 and measured the fraction of proliferating cells (Ki67þ ) in
the basal layer of six tissue sections. In agreement with previous
in vivo experiments (Proksch et al, 1991; Denda et al, 1996), we
found that 24 h after acetone treatment the fraction of
proliferating cells increased 4-fold, from 5.4% to 21.6% (Fig 6;
p¼ 0.0002). This result supports the functional signi¢cance of
microarray data and con¢rms the similarity of the engineered
skin with the natural tissue.
DISCUSSION
We used engineered skin equivalents as a model system to study
gene expression in response to barrier disruption. As skin equiva-
lents show a complete program of terminal di¡erentiation with
all epidermal cell layers and a functional stratum corneum, they
are an excellent model system that can be used in controlled ex-
periments. The absence of other cell types, such as ¢broblasts and
endothelial cells, may result in lack of cell^cell interactions that
may a¡ect the response of keratinocytes. The main contribution
to barrier function comes from the stratum corneum, however,
which is the result of terminal di¡erentiation of the epidermis.
Therefore, the response of skin to barrier disruption stems mainly
from epidermal keratinocytes. In addition, skin equivalents can
be used to address the importance of cell^cell interactions in re-
sponse to barrier disruption by incorporation of other cell types,
e.g., ¢broblasts or dendritic cells, in the tissue. This is currently
under investigation in our laboratories.
Multiple genes involved in every aspect of cellular life were
found to change in response to acetone treatment. Genes in-
volved in cell adhesion and regulation of tight junctions (e.g.,
EMS-1; Table II) showed decreased expression. Similarly, genes
encoding for structural components of the corni¢ed envelope
such as strati¢n, corneodesmosin, calgranulin A and B also
showed decreased expression, indicating that acetone had a major
e¡ect on the upper layers of the epidermis. In contrast, acetone
led to expression of several growth- and cell-cycle-related genes
such as EGR-1 (Riggs et al, 2000), CREB2 (Flint and Jones, 1991;
Guo et al, 1997), cyclin K (Edwards et al, 1998), amphiregulin
(Piepkorn et al, 1995; Piepkorn, 1996; Liou et al, 1997), and CLK
(Arany et al, 1996; Gibbs et al, 2002). These molecular events were
accompanied by increased proliferation of the engineered epider-
mis, which is in agreement with previous in vivo studies (Denda
et al, 1996; Ashida et al, 2001).
Interestingly, barrier disruption caused a signi¢cant early upre-
gulation of in£ammation-related genes like IL2-Ra and T-cell-
speci¢c RANTES, which decreased at later times. RANTES is
chemotactic for memory T cells and activated naive T cells. It is
expressed by keratinocytes of psoriatic skin, where it is suspected
to enhance migration of the activated T cells to the epidermis of
the psoriatic lesions (Fukuoka et al, 1998; Raychaudhuri et al,
1999). Others have demonstrated that acute barrier disruption by
acetone treatment or tape stripping increased the T cell activating
ability of epidermal cells in vivo (Nishijima et al, 1997). Our data
with tissue-engineered skin con¢rm the immune-stimulatory
ability of epidermal keratinocytes (Langerhans cells are not pre-
sent in our skin equivalents) that may be necessary to eliminate
environmental agents that penetrate easily through the compro-
mised epidermis. After boosting immune reactivity the epidermis
upregulates genes related to fatty acid synthesis like ACBP and
PLA2, which may be important for the recovery of the barrier
function. Indeed, others have shown that acetone treatment or
tape stripping induces epidermal upregulation of genes related
to fatty acid transport and synthesis to restore the barrier (Harris
et al, 1998).
In summary, our results suggest that the epidermis reacts to
acetone-mediated barrier disruption through a two-wave re-
sponse (Fig 7). At early times postinjury, engineered epidermis
upregulates genes involved in survival, growth, and in£amma-
tion, possibly as a way to protect the cells from injury and to sig-
nal other neighboring cells about the compromised barrier. At
later times the in£ammation-related gene expression decreases
and genes involved in lipid metabolism return to their normal
levels, suggesting that the engineered tissue switches to a di¡er-
entiation mode and synthesizes lipids to restore the barrier.
Recently, gene array hybridization has been used to identify
the changes in gene expression when skin keratinocytes were ex-
posed to UVB radiation (Li et al, 2001; Sesto et al, 2002; Urschitz
et al, 2002) and when skin was subjected to injury (Cole et al,
2001b) or burn (Spies et al, 2002). Similar to treatment with acet-
Figure 4. Gene clusters using SOM. The 154 genes that passed the cri-
teria were grouped into nine groups. The ratios are represented on the y
axis and the time points on the x axis. The middle line (black, solid) repre-
sents the average expression of a gene belonging to each cluster and the
other two lines (gray, dashed) indicate the standard deviation. The numbers
in each panel show the number of genes belonging to the corresponding
cluster.
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one UVB induced expression of a broad range of genes including
transcription factors and genes involved in transcription, signal
transduction, cytoskeletal function, and DNA synthesis. For ex-
ample, certain transcription factors such as EGR-1 and ETR101
were induced by both UV and acetone treatments. Similarly,
UV, burn injury, and acetone treatment suppressed metabolic ac-
tivities including those related to lipid metabolism, possibly to
preserve energy for other functions related to survival and in-
£ammation.
Several di¡erences are also evident between the acetone- and
UV-treated cells. For example the transcription factor hypoxia-
inducible factor (HIF-1a) was induced by UV (Sesto et al, 2002)
but suppressed by acetone. On the other hand, c-Myc showed a
strong and persistent decrease in response to UV (Li et al, 2001)
but a transient increase (at 4 h) in response to acetone. As UV
irradiation causes DNA damage, c-Myc may decrease to prevent
proliferation of cells with damaged DNA that may result in tu-
mor formation. In contrast, c-Myc was upregulated in response to
acetone possibly to stimulate proliferation and barrier recovery.
Similarly, whereas UV suppresses amphiregulin and HSP40, acet-
one induces amphiregulin and other heat shock proteins, namely
HSP70 and HSP90. Therefore, comparison of the global response
of skin cells to di¡erent environmental insults may reveal mole-
cular pathways that may uniquely characterize each type of in-
jury, ultimately leading to better medical treatments. In this
regard, engineered tissues may provide useful model systems for
well-controlled studies.
Figure 5. Comparison of the expression ratios of selected genes measured by real-time PCR and microarrays. Real-time PCRwas performed
for four genes: FRA-1 (A), EGR-1 (B), thymosin b10 (C), and PLA2 (D). The ratios were calculated as described in Materials and Methods and plotted as a
function of time. Each point corresponds to the mean of triplicate samples in a representative experiment (n¼ 2).
Figure 6. Acetone induced hyperproliferation in the basal layer of
skin equivalents. Skin equivalents were wounded by application of acet-
one in the tissue culture inserts for 10 min. The acetone was removed, fresh
medium was added in the lower compartment, and the tissues were re-
turned to culture at the air^liquid interface. At 24 h para⁄n sections were
stained for the proliferation antigen Ki67.The fraction of proliferating basal
cells (Ki67þ ) was counted in six randomly selected ¢elds of view. The dif-
ference between wounded and unwounded tissues was statistically signi¢-
cant (p¼ 0.0001). The results are representative of three independent
experiments.
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We propose that functional genomics can be used in tissue en-
gineering to study organogenesis, disease pathophysiology, or re-
sponse of engineered tissues to chemical or biologic treatments.
Global gene expression pro¢les provide molecular ‘‘signatures’’
that may be used to evaluate engineered tissues and develop mo-
lecular criteria to assess their suitability for transplantation. Geno-
mic and proteomic technologies may also facilitate the
development of tissue-engineered models of human disease to in-
crease our understanding of disease pathophysiology and facili-
tate drug development and testing. Finally, engineered tissues
may be used as reliable in vitro models to monitor the e¡ects of
chemical and biologic agents or environmental hazards minimiz-
ing the need for animal experiments. High throughput DNA or
protein arrays may be very useful in monitoring the response of
tissue-based biosensors and as screening tools to identify speci¢c
biomarkers of tissue response to certain treatments. Therefore, ap-
plication of bioinformatics in tissue engineering has the potential
to signi¢cantly impact modern medicine and the health care in-
dustry.
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